$MDT

Medtronic plc (MDT) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events On September 14, 2026, Medtronic plc, a public limited company organized under the laws of Ireland (“Medtronic”), commenced an offer to exchange (the “Exchange Offer”) up to 225,361,295 newly issued shares of common stock, par value $0.01 per share (“MiniM

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 1,483 shares of Medtronic plc (MDT) at $93.65 ($0.14M total) on 2026-09-16.

Medtronic (MDT) shares are down 3% this year, but the company's Hugo robotic-assisted surgery system is gaining market share. The FDA approved Hugo for urological procedures, and Medtronic submitted new filings for broader use. Q1 2027 revenue was $9.8B, up 13.7% YoY, with EPS of $1.14, up 40.7%. The company raised full-year guidance and is on track to become a Dividend King. Medtronic's dividend yield is 3.06%, and it is expanding in cardiac and spinal technologies.

Medtronic (MDT) raised its fiscal 2027 profit forecast to $5.94-$6.00 per share and increased revenue growth outlook to 7.25%-7.75%. Q1 revenue was $9.756B, up 13.7%, with all segments showing double-digit growth. The company faces tariff headwinds and potential diabetes business separation.

Boston Scientific (BSX) and Medtronic (MDT) compete in the $16.73B electrophysiology market, projected to grow at 14.31% CAGR. BSX has declined 2.1% in 3 months, while MDT gained 18.6%. BSX faces near-term challenges in electrophysiology but has long-term growth opportunities. MDT shows strong growth in cardiovascular and robotic surgery. Analysts project BSX's 2026 EPS at $3.29, down 1.8% in 60 days, while MDT's fiscal 2027 EPS is estimated at $5.97, up 0.5%.

Medtronic (MDT) reported Q1 growth of 7% (excluding an extra week), driven by innovations in cardiac ablation, renal denervation, robotics, and pelvic health. Cardiac ablation revenue surpassed $2B, while pelvic health revenue grew 15%. The company is investing in robotics, structural heart, and neuroscience, and plans to focus on tuck-in acquisitions. Medtronic expects to discuss its growth outlook further at an upcoming Investor Day.

Medtronic (MDT) received FDA clearance for its LigaSure™ RAS Maryland instrument for use with the Hugo™ RAS robotic-assisted surgery system in the U.S. The device, already used in over 45 million procedures globally, expands the Hugo system's capabilities. Medtronic aims to broaden the system's applications in the U.S. and continues its international expansion.

Medtronic (MDT) appointed Lara Barghout, former CEO of Recor Medical, as president of its Interventional Cardiology Therapies unit. Barghout brings extensive experience in cardiovascular medtech. Medtronic also announced the departure of Jason Fontana, VP and RDN GM, after 20 years.

Medtronic (MDT) is offering shareholders the option to exchange their ordinary shares for shares of MiniMed, a company being separated from Medtronic. Participation is voluntary, and eligible shares must have been held for at least one year. The exchange offer expires on October 9, 2026, with specific deadlines for tendering and withdrawing shares. Medtronic and MiniMed have filed relevant documents with the SEC.

Medtronic PLC's stock rose 3.12% to $93.80 on Monday, ending a four-day losing streak, while the S&P 500 and Dow Jones indices fell 0.48% and 0.29%, respectively.